2023
Occupational Risk Factors for SARS-CoV-2 Seropositivity in Healthcare Workers
Fazen L, Abad Q, Smith R, Santiago R, Liu J, Wisnewski A, Redlich C. Occupational Risk Factors for SARS-CoV-2 Seropositivity in Healthcare Workers. Journal Of Occupational And Environmental Medicine 2023, 65: 521-528. PMID: 36893070, PMCID: PMC10227858, DOI: 10.1097/jom.0000000000002831.Peer-Reviewed Original ResearchConceptsHealthcare workersRisk factorsSARS-CoV-2 immunoglobulin GSARS-CoV-2 seropositivityMultivariable-adjusted logistic regressionCox proportional hazards modelVaccine-induced immunityCOVID-19 risk factorsOccupational risk factorsLongitudinal cohort studyProportional hazards modelOccupational health interventionsRole of physiciansCOVID-19 riskCohort studyHazards modelHealth interventionsInternal medicineLogistic regressionResident physiciansImmunoglobulin GPhysiciansCOVID-19 pandemicSeropositivityVaccination
2022
Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue
Wisnewski AV, Cantley L, Luna J, Liu J, Smith RF, Hager K, Redlich CA. Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue. Journal Of Occupational And Environmental Medicine 2022, 64: 788-796. PMID: 36054278, PMCID: PMC9426317, DOI: 10.1097/jom.0000000000002617.Peer-Reviewed Original ResearchConceptsOccupational risk factorsCOVID-19 historyRisk factorsAnti-spike IgG levelsIndividual humoral responsesSerum antiviral antibodiesCOVID-19 vaccinationEnzyme-linked immunosorbent assayCOVID-19 ratesCOVID-19 incidenceSpike IgGVaccine nonrespondersVaccination statusIgG levelsVaccine responsesVaccine typesAntiviral antibodiesHumoral responseCOVID-19 casesVaccine availabilityImmunosorbent assayVaccinationInfectionMonthsParticipants
2021
Human IgG and IgA responses to COVID-19 mRNA vaccines
Wisnewski AV, Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0249499. PMID: 34133415, PMCID: PMC8208542, DOI: 10.1371/journal.pone.0249499.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccinesAntigen-specific IgGMRNA vaccinesIgG levelsCOVID-19 mRNA vaccinationAntigen-specific IgG levelsInitial vaccine doseAntigen-specific IgASARS-CoV-2More rapid declineSecond vaccineVaccine doseMRNA vaccinationIgA responsesSerum levelsVaccine dosesSpecific IgGNatural immunityViral neutralizationIgAVaccinePeak levelsIgGVaccinationHuman IgG